Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1982 1
1985 2
1986 3
1987 6
1988 4
1989 4
1990 1
1991 1
1992 1
1993 1
1994 3
1995 2
1996 3
1997 5
1998 3
1999 6
2000 3
2001 4
2002 7
2003 7
2004 12
2005 17
2006 8
2007 17
2008 21
2009 13
2010 22
2011 11
2012 16
2013 20
2014 33
2015 19
2016 30
2017 35
2018 38
2019 29
2020 18
2021 38
2022 30
2023 27
2024 34
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

518 results

Results by year

Filters applied: . Clear all
Page 1
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Among authors: yang gh. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, Wang XY, Sun L, Ge NL, Huang XW, Qiu SJ, Yang XR, Gao Q, He YF, Xu Y, Sun J, Ren ZG, Fan J, Zhou J. Shi GM, et al. Among authors: yang gh. Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7. Signal Transduct Target Ther. 2023. PMID: 36928584 Free PMC article. Clinical Trial.
Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.
Zhang DH, Liang C, Hu SY, Huang XY, Yu L, Meng XL, Guo XJ, Zeng HY, Chen Z, Zhang L, Pei YZ, Ye M, Cai JB, Huang PX, Shi YH, Ke AW, Chen Y, Ji Y, Shi YG, Zhou J, Fan J, Yang GH, Sun QM, Shi GM, Lu JC. Zhang DH, et al. Among authors: yang gh. J Transl Med. 2024 Oct 1;22(1):883. doi: 10.1186/s12967-024-05670-1. J Transl Med. 2024. PMID: 39354613 Free PMC article.
COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma.
Luo AL, Zheng WY, Zhang Q, Yuan Y, Li MQ, Du K, Gao AR, Pei LJ, Xie J, Chen WH, Zhang L, Guo XZ, Yang XR, Zeng C, Yang GH, Deng M. Luo AL, et al. Among authors: yang gh. Adv Sci (Weinh). 2025 Jun;12(22):e2416360. doi: 10.1002/advs.202416360. Epub 2025 Apr 8. Adv Sci (Weinh). 2025. PMID: 40198582 Free PMC article.
518 results